Rating: High-quality hold / speculative buy on pullbacks Style: Semiconductor IP compounder with AI data-center optionality Core debate: Is Arm becoming the central architecture layer for the AI computing era, or has the market already priced in the full success of its move from neutral IP licensor to direct AI CPU vendor? Executive View Arm is one of the highest-quality business models in semiconductors.Read more

StoneX quietly sits behind the scenes of global trading and money movement, and it tends to do best when markets get choppy and customers need to hedge, trade, and move cash across borders. A major acquisition makes it a bigger player in futures and clearing, but the key question is whether today’s strong results can hold up if markets calm down.Read more

AST SpaceMobile is moving from demos to putting real satellites in orbit to bring phone service to regular smartphones in places where towers can’t reach. Big carrier tie-ups and early government work add credibility, but the plan still hinges on flawless launches and smooth rollout in a crowded satellite race.Read more

Rigetti is starting to look less like a science project and more like a real supplier, with early signs that customers are actually buying its quantum machines and using its cloud access. The catch: the company is still burning cash and has to hit tough technical goals, so even small stumbles could hit confidence fast.Read more

IonQ is pulling ahead in the race to turn quantum computing from lab work into real customer work, with growing demand and a broader push into related technologies like networking and manufacturing. But the market already treats it like a sure long-term winner, so even a small stumble in execution or the tech roadmap could hit the stock hard.Read more

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more

Rating: Buy / Quality recovery compounder Style: Mid-cap consumer compounder with cyclical film-slate exposure Core debate: Is Kinepolis just a movie-theatre operator in a structurally challenged industry, or is it a premium cinema platform with better economics, stronger pricing power, and more durable cash generation than the market gives it credit for? Executive view Kinepolis is not a “cinema recovery trade” in the simple sense.Read more

Rating: Speculative / Venture-style public equity Style: Pre-revenue aerospace development story Core debate: Is Horizon Aircraft a differentiated eVTOL platform with a more practical mission profile than many peers, or is it still too early, too capital-intensive, and too uncertain to justify meaningful equity upside today? Executive view Horizon Aircraft is not an established aerospace manufacturer.Read more

Rating: Speculative Buy / High-risk value Style: Leveraged offshore E&P recovery Core debate: Is Kosmos just another debt-heavy small-cap oil and gas producer, or is it an underappreciated offshore cash-flow story with improving production, falling costs, and meaningful equity upside if management keeps deleveraging? Executive view Kosmos is not a “quality compounder” in the way Prysmian or Quanta are.Read more